Protalix BioTherapeutics CEO Moshe Manor's 2019 pay slips 14% to $616K
Protalix BioTherapeutics reports 2019 executive compensation
By ExecPay News
Published: April 15, 2020
Protalix BioTherapeutics reported fiscal year 2019 executive compensation information on April 15, 2020.
In 2019, seven executives at Protalix BioTherapeutics received on average a compensation package of $392K, a 23% decrease compared to previous year.
Average pay of disclosed executives at Protalix BioTherapeutics
Moshe Manor, Chief Executive Officer, received $616K in total, which decreased by 14% compared to 2018. 59% of Manor's compensation, or $362K, was in salary. Manor also received $39K in option awards and $214K in other compensation.
Yoseph Shaaltiel, Executive Vice President, Research and Development, received a compensation package of $468K, which increased by 8% compared to previous year. 62% of the compensation package, or $291K, was in salary.
Einat Brill Almon, Senior Vice President, Product Development, earned $422K in 2019, a 16% decrease compared to previous year.
Dror Bashan, Chief Executive Officer, received $392K in 2019.
Yaron Naos, Senior Vice President, Operations, earned $386K in 2019, a 14% increase compared to previous year.
Yossi Maimon, Chief Financial Officer, received $306K in 2019, which decreases by 45% compared to 2018.
Eyal Rubin, Chief Financial Officer, earned $154K in 2019.
Related executives
Dror Bashan
Protalix BioTherapeutics
Chief Executive Officer
Moshe Manor
Protalix BioTherapeutics
Chief Executive Officer
Yoseph Shaaltiel
Protalix BioTherapeutics
Executive Vice President, Research and Development
Einat Almon
Protalix BioTherapeutics
Senior Vice President, Chief Development Officer
Eyal Rubin
Protalix BioTherapeutics
Chief Financial Officer
Yossi Maimon
Protalix BioTherapeutics
Chief Financial Officer
Yaron Naos
Protalix BioTherapeutics
Senior Vice President, Operations
You may also like
Source: SEC filing on April 15, 2020.